The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote

Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.